CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $2.35 billion. The enterprise value is $1.78 billion.
Market Cap | 2.35B |
Enterprise Value | 1.78B |
Important Dates
The next estimated earnings date is Friday, August 2, 2024, before market open.
Earnings Date | Aug 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 66.64 million shares outstanding. The number of shares has increased by 1,158.12% in one year.
Shares Outstanding | 66.64M |
Shares Change (YoY) | +1,158.12% |
Shares Change (QoQ) | +811.42% |
Owned by Insiders (%) | 7.05% |
Owned by Institutions (%) | 72.12% |
Float | 43.68M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 4,354.48 |
Forward PS | 2,899.90 |
PB Ratio | 4.13 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 3,304.20 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 57.95, with a Debt / Equity ratio of 0.00.
Current Ratio | 57.95 |
Quick Ratio | 56.76 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $8,836 |
Profits Per Employee | -$932,328 |
Employee Count | 61 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 32.67 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 54.83 |
Average Volume (20 Days) | 511,840 |
Short Selling Information
The latest short interest is 5.35 million, so 8.03% of the outstanding shares have been sold short.
Short Interest | 5.35M |
Short Previous Month | 4.30M |
Short % of Shares Out | 8.03% |
Short % of Float | 12.24% |
Short Ratio (days to cover) | 4.11 |
Income Statement
In the last 12 months, CG Oncology had revenue of $539,000 and -$56.87 million in losses. Loss per share was -$0.85.
Revenue | 539,000 |
Gross Profit | n/a |
Operating Income | n/a |
Pretax Income | n/a |
Net Income | -56.87M |
EBITDA | n/a |
EBIT | n/a |
Loss Per Share | -$0.85 |
Balance Sheet
The company has $566.51 million in cash and $404,000 in debt, giving a net cash position of $566.10 million or $8.49 per share.
Cash & Cash Equivalents | 566.51M |
Total Debt | 404,000 |
Net Cash | 566.10M |
Net Cash Per Share | $8.49 |
Equity (Book Value) | 568.94M |
Book Value Per Share | 8.54 |
Working Capital | 568.63M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | -10,551.39% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,158.12% |
Shareholder Yield | -1,158.12% |
Earnings Yield | -2.42% |
FCF Yield | n/a |
Analyst Forecast
The average price target for CG Oncology is $64.00, which is 81.72% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $64.00 |
Price Target Difference | 81.72% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 357.04% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |